Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinsearch LLC

Neither a doctor nor a teaching hospital

Research payments

$70,404

12 payments

Through program year 2025, Clinsearch LLC is reported as receiving $70,404 in research payments, across 12 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $173 1
2024 Research $161 1
2023 Research $743 2
2022 Research $749 1
2021 Research $886 1
2020 Research $25,944 3
2019 Research $41,747 3

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $41,747 3 payments
  2. Allergan Inc. $22,821 2 payments
  3. Eli Lilly and Company $5,836 7 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc $22,663 2 payments
  2. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc $19,085 1 payment
  3. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $17,304 1 payment
  4. A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $5,517 1 payment
  5. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-1) $4,009 2 payments
  6. A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of Ly3209590 Administered Weekly Using A Fixed Dose Escalation Compared to Insulin Glargine in Insulin-Naive Adults With Type 2 Diabetes $749 1 payment
  7. A Study of Ly3298176 (Tirzepatide) for the Maintenance of Body Weight Reduction in Participants Who Have Obesity Or Overweight With Weight-Related Comorbidities $598 1 payment
  8. A Study of Ly3298176 (Tirzepatide) for the Maintenance of Body Weight Reduction in Participants Who Have Obesity Or Overweight With Weight-Related Comorbidities $335 2 payments
  9. A Phase 3 Parallel-Design Open-Label Randomized Control Study to Evaluate the Efficacy and Safety of Ly3209590 Administered Weekly Using A Fixed Dose Escalation Compared to Insulin Glargine in Insulin-Naive Adults With Type 2 Diabetes $145 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record